Compare Quest Diagnostics Inc (DGX) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Trade Desk Inc — how do they compare? Quest Diagnostics Inc trades at $237.17 (market cap $26.21B), while Trade Desk Inc trades at $13.28 (market cap $6.37B). The key difference: Quest Diagnostics Inc is far larger — about 4.1× Trade Desk Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| DGX | TTD | |
|---|---|---|
Market Cap | $26.21B | $6.37B |
Sector | Health | Technology |
52-Week High | $238.50 | $55.36 |
52-Week Low | $173.49 | $13.39 |
Enterprise Value | $31.97B | $5.32B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
The Trade Desk (TTD) stock trades at $13.39, down 2.97% today and near 52-week lows after a sharp 90% decline from its 2024 peak. Recent Q2 2026 earnings missed expectations with 3% revenue growth and weak Q3 guidance, triggering analyst downgrades. Technical indicators are bearish, with support at $12. The company maintains strong profitability margins but faces growth deceleration and competitive pressures in digital advertising.
Outlook remains cautious due to execution gaps and macroeconomic headwinds. While valuations appear reasonable with a P/E of 16.14, near-term risks from revenue declines and advertiser pullbacks outweigh potential upside. Investors should monitor Q3 earnings for signs of stabilization before considering entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
